Biogen and UCB’s lupus drug reached sustained remission in more patients. Why the real test is still two years away
New Phase 3 analyses strengthen dapirolizumab’s lupus profile, but Biogen and UCB still need PHOENYCS FLY to confirm efficacy.
Pharma & Biotech
Pharma & Biotech
Innoviva’s antibiotics are growing 45%, so why did the company report a $73.9m loss?
Innoviva reported strong growth in its infectious disease and critical care medicines, supported by increasing XACDURO sales and the commercial launch of Nuzolvence. However, a substantial non-cash decline in the value of healthcare investments produced a quarterly net loss despite improving operating profitability.
Pharma & Biotech
Why GSK’s wet-lab validation gives Chai Discovery a stronger pharmaceutical industry foothold
GSK expands Chai Discovery AI collaboration after wet-lab success. See what the binding results establish and what remains unproven.
Pharma & Biotech
GSK’s Ris-Rez cuts death risk 54% in relapsed small cell lung cancer as ADC pipeline gains weight
GSK’s licensed B7-H3 antibody-drug conjugate Ris-Rez delivered median survival of 18.5 months versus 10.3 months with topotecan in a Chinese Phase 3 study, strengthening the company’s case for global development.
Pharma & Biotech
What does Samsung Biologics’ new $262m Songdo manufacturing deal signal?
Samsung Biologics adds a $262 million manufacturing deal through 2033 as its capacity, acquisitions and global CDMO ambitions expand.
Pharma & Biotech
A US$2.5bn AI drug alliance is taking shape, but what have Insilico and Bora actually agreed?
Insilico Medicine and Bora Pharmaceuticals propose an AI drug alliance worth over US$2.5 billion, but definitive agreements remain pending.
Pharma & Biotech
Hansoh Pharma’s Ris-Rez improves survival in Phase 3 small-cell lung cancer trial
Hansoh Pharmaceutical Group Co., Ltd. has reported that risvutatug rezetecan, also known as Ris-Rez or HS-20093, significantly improved overall survival in the pivotal Phase 3 ARTEMIS-008 trial involving Chinese patients with advanced or relapsed small-cell lung cancer following platinum-based treatment. The B7-H3-directed antibody-drug conjugate was compared with topotecan and also produced a consistent benefit in
Pharma & Biotech
Why Sino Biopharmaceutical’s twin respiratory deals may worry global pharma rivals
Sino Biopharmaceutical Limited has secured two respiratory medicine transactions involving AstraZeneca PLC and GSK plc, strengthening both its out-licensing and China commercialization strategy. Its subsidiary Chia Tai Tianqing Pharmaceutical Group granted AstraZeneca exclusive rights outside China to develop, manufacture and commercialize TQC3721, an investigational PDE3/4 inhibitor for chronic respiratory disease, while separately obtaining mainland China
Pharma & Biotech
GSK and Spero win Utebzi approval after an earlier FDA rejection and new Phase 3 trial
The first United States-approved oral carbapenem could replace intravenous therapy for selected complicated urinary tract infections, but stewardship, four-times-daily dosing and resistance risks will constrain its use.
Pharma & Biotech
Myriad Genetics expands precision oncology role with Zejula companion diagnostic approval
Myriad Genetics secures FDA approval for MyChoice CDx in ovarian cancer. Discover how HRD testing could reshape PARP inhibitor treatment decisions.